Elizabeth Garrett-Mayer to Antineoplastic Agents
This is a "connection" page, showing publications Elizabeth Garrett-Mayer has written about Antineoplastic Agents.
Connection Strength
0.793
-
Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with acute myelogenous leukemia and poor-risk features. Clin Cancer Res. 2008 May 15; 14(10):3077-82.
Score: 0.176
-
Functional oncogene signatures guide rationally designed combination therapies to synergistically induce breast cancer cell death. Oncotarget. 2016 Jun 14; 7(24):36138-36153.
Score: 0.077
-
A feasibility study of cyclophosphamide, trastuzumab, and an allogeneic GM-CSF-secreting breast tumor vaccine for HER2+ metastatic breast cancer. Cancer Immunol Res. 2014 Oct; 2(10):949-61.
Score: 0.068
-
Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis. EMBO Mol Med. 2013 01; 5(1):105-21.
Score: 0.060
-
Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast cancer. Breast Cancer Res Treat. 2011 May; 127(1):153-62.
Score: 0.053
-
Toxicity and survival outcomes of hyperfractionated split-course reirradiation and daily concurrent chemotherapy in locoregionally recurrent, previously irradiated head and neck cancers. Head Neck. 2009 Apr; 31(4):493-502.
Score: 0.047
-
Tamoxifen-stimulated growth of breast cancer due to p21 loss. Proc Natl Acad Sci U S A. 2008 Jan 08; 105(1):288-93.
Score: 0.043
-
Risks and benefits associated with novel phase 1 oncology trial designs. Cancer. 2007 Sep 01; 110(5):1115-24.
Score: 0.042
-
Development of two novel benzoylphenylurea sulfur analogues and evidence that the microtubule-associated protein tau is predictive of their activity in pancreatic cancer. Mol Cancer Ther. 2007 May; 6(5):1509-16.
Score: 0.041
-
Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study. J Urol. 2007 May; 177(5):1777-81.
Score: 0.041
-
A prostate-specific antigen-activated channel-forming toxin as therapy for prostatic disease. J Natl Cancer Inst. 2007 Mar 07; 99(5):376-85.
Score: 0.041
-
Phase II study of imatinib mesylate in patients with prostate cancer with evidence of biochemical relapse after definitive radical retropubic prostatectomy or radiotherapy. Urology. 2007 Mar; 69(3):526-31.
Score: 0.041
-
Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer. J Natl Cancer Inst. 2003 Jul 02; 95(13):990-1000.
Score: 0.031
-
Inhibition of sphingosine kinase 2 downregulates the expression of c-Myc and Mcl-1 and induces apoptosis in multiple myeloma. Blood. 2014 Sep 18; 124(12):1915-25.
Score: 0.017
-
Primary chemoprevention of familial adenomatous polyposis with sulindac. N Engl J Med. 2002 Apr 04; 346(14):1054-9.
Score: 0.007
-
A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations. Blood. 2001 Aug 01; 98(3):885-7.
Score: 0.007